Literature DB >> 25388535

Bile acid derivatives as ligands of the farnesoid x receptor: molecular determinants for bile acid binding and receptor modulation.

Antimo Gioiello, Bruno Cerra, Serena Mostarda, Chiara Guercini, Roberto Pellicciari, Antonio Macchiarulo1.   

Abstract

Bile acids are a peculiar class of steroidal compounds that never cease to amaze. From being simple detergents with a primary role in aiding the absorption of fats and fat-soluble vitamins, bile acids are now widely considered as crucial hormones endowed with genomic and non-genomic functions that are mediated by their interaction with several proteins including the nuclear receptor Farnesoid X Receptor (FXR). Taking advantages of the peculiar properties of bile acids in interacting with the FXR receptor, several biliary derivatives have been synthesized and tested as FXR ligands. The availability of these compounds has contributed to characterize the receptor from a structural, patho-physiological and therapeutic standpoint. Among these, obeticholic acid is a first-in-class FXR agonist that is demonstrating hepatoprotective effects upon FXR activation in patients with liver diseases such as primary biliary cirrhosis and nonalcoholic steatohepatitis. This review provides an historical overview of the rationale behind the discovery of obeticholic acid and chemical tools generated to depict the molecular features and bio-pharmacological relevance of the FXR receptor, as well as to summarize structure-activity relationships of bile acid-based FXR ligands so far reported.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25388535     DOI: 10.2174/1568026614666141112100208

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  6 in total

1.  The association between gut microbiota development and maturation of intestinal bile acid metabolism in the first 3 y of healthy Japanese infants.

Authors:  Masaru Tanaka; Masafumi Sanefuji; Seiichi Morokuma; Misako Yoden; Rie Momoda; Kenji Sonomoto; Masanobu Ogawa; Kiyoko Kato; Jiro Nakayama
Journal:  Gut Microbes       Date:  2019-09-24

Review 2.  Animal models of gastrointestinal and liver diseases. Animal models of acute and chronic pancreatitis.

Authors:  Xianbao Zhan; Fan Wang; Yan Bi; Baoan Ji
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-07-14       Impact factor: 4.052

3.  Weak Microbial Metabolites: a Treasure Trove for Using Biomimicry to Discover and Optimize Drugs.

Authors:  Zdenek Dvorak; Max Klapholz; Thomas P Burris; Benjamin P Willing; Antimo Gioiello; Roberto Pellicciari; Francesco Galli; John March; Stephen J O'Keefe; R Balfour Sartor; Chang H Kim; Maayan Levy; Sridhar Mani
Journal:  Mol Pharmacol       Date:  2020-08-06       Impact factor: 4.436

Review 4.  Farnesoid X receptor: a potential therapeutic target in multiple organs.

Authors:  Chao Zhang; Zixuan Wang; Qingqing Feng; Wei-Dong Chen; Yan-Dong Wang
Journal:  Histol Histopathol       Date:  2021-01-04       Impact factor: 2.303

5.  Synthesis and biological evaluations of chalcones, flavones and chromenes as farnesoid x receptor (FXR) antagonists.

Authors:  Guoning Zhang; Shuainan Liu; Wenjuan Tan; Ruchi Verma; Yuan Chen; Deyang Sun; Yi Huan; Qian Jiang; Xing Wang; Na Wang; Yang Xu; Chiwai Wong; Zhufang Shen; Ruitang Deng; Jinsong Liu; Yanqiao Zhang; Weishuo Fang
Journal:  Eur J Med Chem       Date:  2017-02-20       Impact factor: 6.514

6.  The glucocorticoid mometasone furoate is a novel FXR ligand that decreases inflammatory but not metabolic gene expression.

Authors:  Ingrid T G W Bijsmans; Chiara Guercini; José M Ramos Pittol; Wienand Omta; Alexandra Milona; Daphne Lelieveld; David A Egan; Roberto Pellicciari; Antimo Gioiello; Saskia W C van Mil
Journal:  Sci Rep       Date:  2015-09-15       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.